Prostate mpMRI in the UK: the state of the nation

Davies, Charlotte; Castle, Joanna T.; Stalbow, K.; Haslam, Philip

doi:10.1016/j.crad.2019.09.129

Cited by 27 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first study to report MRF of the prostate performed at 1.5T, which is still commonly used for routine prostate imaging [26]. The observed high cross-system reproducibility of prostate MRF T 1 is similar to that reported in the brain by Buonincontri et al, suggesting the overall robustness of MRF to field-dependent variation of T 1 [30].…”

Section: Plos Onesupporting

confidence: 78%

“…Several pilot studies investigating the added value of MRF to prostate mpMRI have demonstrated significantly improved detection of clinically significant peripheral zone (PZ) and transition zone (TZ) tumors when MRF was used in combination with apparent diffusion coefficient (ADC) mapping [20][21][22][23]. However, wider clinical validation of MRF as part of an mpMRI protocol is limited by the fact studies have only validated performance on 3T MRI systems, whist the majority of prostate mpMRI scans even in developed countries are still performed on 1.5T scanners [24][25][26][27]. The most recent version of the PI-RADS guidelines (v2.1) suggest that both 1.5T and 3T allow for reliable diagnostic exams in the context of adequate hardware and software, and when optimal acquisition parameters are ensured.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study

et al. 2021

View full text Add to dashboard Cite

Facilitating clinical translation of quantitative imaging techniques has been suggested as means of improving interobserver agreement and diagnostic accuracy of multiparametric magnetic resonance imaging (mpMRI) of the prostate. One such technique, magnetic resonance fingerprinting (MRF), has significant competitive advantages over conventional mapping techniques in terms of its multi-site reproducibility, short scanning time and inherent robustness to motion. It has also been shown to improve the detection of clinically significant prostate cancer when added to standard mpMRI sequences, however, the existing studies have all been conducted on 3.0 T MRI systems, limiting the technique’s use on 1.5 T MRI scanners that are still more widely used for prostate imaging across the globe. The aim of this proof-of-concept study was, therefore, to evaluate the cross-system reproducibility of prostate MRF T1 in healthy volunteers (HVs) using 1.5 and 3.0 T MRI systems. The initial validation of MRF T1 against gold standard inversion recovery fast spin echo (IR-FSE) T1 in the ISMRM/NIST MRI system revealed a strong linear correlation between phantom-derived MRF and IR-FSE T1 values was observed at both field strengths (R2 = 0.998 at 1.5T and R2 = 0.993 at 3T; p = < 0.0001 for both). In young HVs, inter-scanner CVs demonstrated marginal differences across all tissues with the highest difference of 3% observed in fat (2% at 1.5T vs 5% at 3T). At both field strengths, MRF T1 could confidently differentiate prostate peripheral zone from transition zone, which highlights the high quantitative potential of the technique given the known difficulty of tissue differentiation in this age group. The high cross-system reproducibility of MRF T1 relaxometry of the healthy prostate observed in this preliminary study, therefore, supports the technique’s prospective clinical validation as part of larger trials employing 1.5 T MRI systems, which are still widely used clinically for routine mpMRI of the prostate.

show abstract

Section: Plos Onesupporting

confidence: 78%

Section: Introductionmentioning

confidence: 99%

Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Might the COVID‐19 pandemic be the trigger that accelerates uptake of LATP perhaps leading to a permanent shift away from TRUS biopsy beyond the pandemic? MRI use in the UK is already a changing paradigm; 99% stated they use MRI in prostate diagnostic pathway, while it has been reported that 25% of centres were not performing any pre‐biopsy MRI in 2016, which reduced to 13% in 2018 [6]. Will the uptake of LATP follow suit in the changing field of prostate diagnostics?…”

Section: Discussionmentioning

confidence: 99%

A cross‐section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID‐19) era – a shifting paradigm?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…22 However, DTI acquisition is timeconsuming and expertise is required for interpretation, and any additional scanning time needs to be balanced against MRI availability and throughput of patients. 58,59 US is another modality that has been utilized for assessment of the male pelvic floor. The technique is low-cost, available, quick, does not require expert interpretation and offers the advantage of dynamic assessment.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of image‐based prognostic parameters of post‐prostatectomy urinary incontinence: A literature review

2021

View full text Add to dashboard Cite

Abbreviations & Acronyms DTI = diffusion tensor imaging LRP = laparoscopic radical prostatectomy mpMRI = multiparametric magnetic resonance imaging MRI = magnetic resonance imaging MUA = membranous urethra angle MUL = membranous urethral length ORP = open radical prostatectomy PAL = prostate apex length PNF = periprostatic nerve fiber PPUI = post-prostatectomy urinary incontinence RARP = robot-assisted radical prostatectomy RP = radical prostatectomy TPUS = transperineal ultrasound US = ultrasound

show abstract

Prostate mpMRI in the UK: the state of the nation

Cited by 27 publications

References 13 publications

Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study

Reproducibility of magnetic resonance fingerprinting-based T1 mapping of the healthy prostate at 1.5 and 3.0 T: A proof-of-concept study

A cross‐section of UK prostate cancer diagnostics during the coronavirus disease 2019 (COVID‐19) era – a shifting paradigm?

Evaluation of image‐based prognostic parameters of post‐prostatectomy urinary incontinence: A literature review

Contact Info

Product

Resources

About